Tuesday, September 2, 2014

ARCH Venture Partners Raises $400M In Investment Fund

ARCH Venture Partners, which maintains an office in Seattle, said last week that it closed on $400M in subscriptions for its eighth venture fund, ARCH Venture Fund VIII. The company said the fund was originally targeted at $250M. ARCH said the new fund goes towards early stage technology in the areas of healthcare, energy, and materials sectors. ARCH's local investments include Juno Therapeutics, Fate Therapeutics, Theraclone Sciences, Groove Biopharma, and many others.